Generic Plavix: As Bristol Swoons, Broad Implications
Executive SummaryThe immediate ramifications of Bristol and Sanofi's failed authorized generics strategy around Plavix may cripple Bristol, hobble, Sanofi, and make a mint for Canadian generics player Apotex. But the most significant impact may be felt in the long term along the fault line where branded and generics companies meet, compete, and increasingly, deal.
You may also be interested in...
CEOs from Sanofi and GlaxoSmithKline hold forth on how previous years’ preparations have led up to this moment, a post-patent-cliff future for big pharma.